In response to ongoing efforts to fight the opioid crisis, drug companies are working to bring non-addictive opioid pain medication to market. With the FDA’s announcement to postpone the decision to approve a new type of this drug, loxicodegol, Work Comp Central Magazine reached out to myMatrixx Chief Clinical Officer Phil Walls for comment. In the article, Walls shares insights regarding the effect these types of drugs could have for the workers’ comp field.
He notes that while opioids with less addictive potential will come to market eventually — and could certainly affect injured workers — it looks like the industry is not quite there yet.
The piece also discusses the recent myMatrixx clinical brief on the co-prescription of the opioid antidote naloxone for patients taking opioid painkillers.
CLICK HERE to read the full article.